Kornimate/medical-research-clean huggingface dataset:
satisfaction after glaucoma surgery in rural china

Conditions: Glaucoma

Summary: 1. investigate degree of postoperative satisfaction in county level hospital glaucoma patients. 2. investigate the effect of educational intervention affect the degree of satisfaction in glaucoma patients. 3. investigate the effect factors of postoperative satisfaction.

glaucoma is the leading cause of irreversible blindness in china, as elsewhere in the world. in chinese rural settings, where topical glaucoma medication is unlikely to be a practical and sustainable option, surgery is the primary treatment modality for glaucoma. however, it is known that vision is quite likely to decline in the short to medium term after glaucoma surgery, and there are concerns that dis-satisfaction resulting from such vision changes might lead to negative social marketing, affecting uptake not only of glaucoma surgical care but other eye operations (principally cataract) as well. we propose to test the impact on post-operative satisfaction of a multi-media educational intervention designed to give patients a realistic expectation of their post operative course: glaucoma surgery is being performed not to improve vision, but do protect it from future harm, and vision may in fact decline for several weeks post operatively. a randomized controlled design will be used, and subjects undergoing glaucoma surgery will be enrolled at 4 rural county hospitals in rural guangdong province, and randomized to receive the intervention or usual care. the principal outcome will be subjective satisfaction on a previously-tested questionnaire instrument, administered pre-operatively and post-operatively on two occasions in the first month following surgery. patients not returning post-operatively to the surgical facility will be contacted by telephone for administration of the questionnaire. other facility- and patient-related clinical and personal factors expected to influence satisfaction will also be recorded, and adjusted for in all analyses.

Eligibility criteria:
inclusion criteria: * age≥18 years, glaucoma patients who do the peripheral iridectomy or trabeculotomy exclusion criteria: * patients who had been the trabeculotomy, vision≤0.05, severe psychotic disorders and dysgnosia

Keywords: glaucoma surgery educational intervention satisfaction rural
effect of panax ginseng c.a. mey extract on liver function in adults

Conditions: Liver Diseases

Summary: the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of panax ginseng c.a. mey extract on liver function in adults for 8 weeks.

previous studies have indicated that panax ginseng c.a. mey extract may have the ability to improve liver function. therefore, the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of the panax ginseng c.a. mey extract on liver function in adults; the safety of the compound are also evaluate. the investigators examine ast, alt, ggt, and other metabolic parameters at baseline, as well as after 4 and 8 weeks of intervention. sixty adults were administered either 600 mg of panax ginseng c.a. mey extract or a placebo each day for 8 weeks;

Eligibility criteria:
inclusion criteria: * alt ranging from upper limit of reference to three times of upper limit exclusion criteria: * abnormal liver or renal function (i.e., serum aminotransferase activity \> 3 times of upper limit of reference range and serum creatinine concentrations \> 1.2 mg/dl) * diabetes (diagnosed clinically or fasting glucose level \> 126 mg/dl) * history of viral hepatitis or cancer * uncontrolled hypertension * history of serious cardiac disease such as angina or myocardial infarction * history of gastrectomy * history of medication for psychiatric disease * administration of oriental medicine including herbs within the past 4 weeks
objective evaluation of proximal ischemia

Conditions: Intermittent Claudication; Peripheral Vascular Diseases

Summary: the whole study is divided in 4 parallel protocols. the first protocol estimates the reliability of the technique through test-retest recordings. the second protocol aims to prove that exercise tcpo2 is efficient to estimate the benefit of proximal revascularisation on proximal and distal ischemia in patients suffering stage two lower extremity arterial disease. the third protocol aims at estimating with exercise tcpo2 the eventual apparison of proximal ischemia after aorto-bi-femoral bypasses. the last protocol is a transversal study of patients with aorto-bi-femoral bypasses aiming to analyse the presence of proximal and distal symptoms and ischemia. the hypothesis for protocol 2 is that tcpo2 at exercise is significantly improved after surgery at the aortic and primary iliac artery. the hypothesis for protocols 3 and 4 relates on the hypothesis that a significant number of patients benefiting aorto-bi-femoral bypass suffer isolated proximal pain/ischemia after surgery. amendement to the project has been recently validated to study the neurologic and bone complication of chronic vascular ischemia

patients included are submitted to: san diego claudication questionnaire before and during the treadmill test treadmill test(s) through the strandness procedure (2mph 10% slope) transcutaneous oxygen pressure recording before during and after exercise ankle and brachial pressure measurements. neurologic investigation with quantitative sensory testing (qst) and neurophysiological tests for patients included in the sub-group analysing neurologic complication whole body densitometry for patients included in the sub-group analysing osteo-articular complications

Eligibility criteria:
inclusion criteria: * protocol 1 - 3 stage 2 claudication * protocols 2 \& 3 : indication for surgery * protocol 4 : patent aorto bio femoral bypass for more than 4 months * ability to perform a treadmill test exclusion criteria: * stage 4 lead * aortic aneurysm * acute coronary syndrom * claudication of documented non vascular origin (for protocols 1-3 only)

Keywords: intermittent claudication peripheral vascular diseases blood gas monitoring, transcutaneous surgery
analgesia after total knee arthroplasty

Conditions: Analgesia

Summary: the recovery from knee replacement surgery often involves a significant amount of pain. the best way to prevent/treat this pain is unknown. this study will compare two accepted methods of pain control in order to determine which is superior. the first method involves the injection of a solution containing multiple medications into the knee joint at the time of surgery. the second method involves the placement of a catheter adjacent to the femoral nerve which senses pain from the knee. this catheter is used to deliver local anesthetic which serves to block the transmission of pain signals from the nerve. the catheter will be left in place until 2 days after surgery. this method is combined with injection of local anesthetic in a particular area of the knee joint at the time of surgery. patients will be followed until 2 days after surgery in order to determine which method is superior. we believe the second method will be deemed superior.


Eligibility criteria:
inclusion criteria: * asa i, ii, \& iii patients * elective primary total knee arthroplasty * spinal anesthesia exclusion criteria: * patients refusing consent * contraindications to regional anesthesia * pre-existing neurological disease * allergy/contraindication to drugs used in the study * revision knee arthroplasty * patients with chronic pain/on narcotics preoperatively * pre-existing rheumatoid arthritis/ankylosing spondylitis * alcohol or drug abuse * psychiatric disorders * inability to use the outcome assessment tools * wheel chair or walker dependent for mobilization

Keywords: randomized controlled study total knee arthroplasty post operative pain continuous femoral nerve block posterior capsular injection periarticular injection
study on early genetic screening and precise strategy of neonatal critical illness

Conditions: Genetic Screening; Hereditary Disease; Newborn; Stillbirth

Summary: the researchers hope to establish an overall program of early genetic screening for neonatal critical illness in china, and to develop precise intervention strategies to assist clinical diagnosis and treatment of hereditary critical illness.

reducing the rate of neonatal death and disability is an important part of health education in china, and genetic diseases are an important cause of neonatal death. at present, with the development of life support platform technology, the treatment level of critically ill newborns has been rapidly improved. how to quickly diagnose and early precise intervention is the key to further break through the diagnosis and treatment of genetic diseases. based on the "neonatal genome project" carried out in the early stage, the research group based on the genetic diagnosis results of over 10000 cases of neonatal critical illness cohort, studied the genetic disease spectrum of neonatal critical illness in line with the actual situation in china. in terms of detection technology, based on the second-generation sequencing technology, we established a critical illness screening gene sequencing combination including 300 genes; in the aspect of data analysis, an intelligent analysis process integrating clinical phenotype and gene sequencing data was established; in terms of clinical diagnosis and treatment, we cooperated with 5 maternity and children's hospitals in shanghai to carry out multi center clinical verification, and formed the implementation plan of early universal genetic screening for neonatal critical illness. through this project, we will carry out genetic disease screening research on neonatal critical diseases, focus on typical clinical manifestations such as encephalopathy, immunodeficiency, metabolic diseases, and carry out molecular autopsy on neonatal death cases to identify potential genetic causes, so as to provide basis for the research of corresponding early precise intervention strategies, and achieve the purpose of reducing neonatal death and disability rate.

Eligibility criteria:
inclusion criteria: * postnatal age less than 100 days; * perinatal death after 20 weeks of gestation (more than 500 g) * can be retained biological samples for genetic screening; * biological parent or guardian's informed consent. exclusion criteria: * reluctance of parents to use genetic sequencing data for subsequent research; * parents under 18 years of age or incapacitated for decision-making; * subjects older than 100 days; * perinatal death less than 20 weeks of gestation or weight less than 500 g; * inherited metabolic diseases with chromosomal abnormalities; * multiple pregnancies; * lack of access to biological samples from which dna can be extracted; * failure to sign informed consent.
larger dose of spironolactone for the treatment of patients with nonischemic cardiomyopathy

Conditions: Heart Failure, Congestive

Summary: the purpose of this study is to determine whether a larger dose of the aldosterone antagonist spironolactone combined with a lower dose of an ace inhibitor is more effective in reverse left ventricular remodeling in severe congestive heart failure in patients with nonischemic cardiomyopathy.

in the investigators' recent daily clinical practice, they found that the larger dose of the aldosterone antagonist spironolactone combined with a lower dose of an ace inhibitor and the highest tolerable dose of beta blockers could reverse left ventricular remodeling more effectively than a smaller dose of spironolactone. the ventricular remodeling could get back to normal, especially in patients with none-ischaemic cardiomyopathy. the investigators hypothesize that long term use of a larger dose of the aldosterone antagonist spironolactone could reverse left ventricular remodeling by stimulating new myocyte formation. thus, they designed this study to verify its efficacy and safety in reversing left ventricular remodeling in severe congestive heart failure in patients with nonischemic cardiomyopathy. to avoid hyperkalemia, the investigators routinely use larger doses of diuretics in combination with a lower dose of an ace inhibitor to offset the potassium-sparing effects of spironolactone and follow the patients closely.

Eligibility criteria:
inclusion criteria: * new york heart association (nyha) functional class ⅲ or ⅳ * left ventricular ejection fraction (lvef) \<35% * nonischemic cardiomyopathy * preserved renal function: cr ≤2.5 mg/dl in males; cr ≤2.0mg/dl in females exclusion criteria: * hyperkalemia (≥5.0 meg/l) * left ventricular systolic dysfunction with pericardial diseases, congenital heart diseases, pulmonary heart diseases, heart valvular diseases, acute coronary syndrome and short life expectancy.

Keywords: aldosterone antagonists spironolactone left ventricular remodeling
bipolar versus unipolar hemiarthroplasty for patients with a hip fracture

Conditions: Femoral Neck Fractures

Summary: insertion of a hemiarthroplasty is a well established treatment for a dislocated medial hip fracture in elderly patients. the purpose of this study is to compare unipolar and bipolar hemiarthroplasty as a treatment for patients aged 70 years or above with a dislocated medial femoral neck fracture. the study is prospective and randomised, and will be based on questionnaires, clinical examinations, registration of complications and radiographic evaluation at follow up at 3 months, 1 and 3 years postoperatively.


Eligibility criteria:
inclusion criteria: * patients ages 70 years or above * dislocated medial femoral neck fracture (garden type 3-4) * residence in the county of northern jutland, denmark exclusion criteria: * pathologic fracture * failed formerly internally fixed fracture of the affected hip * degenerative joint disease of the affected hip or rheumatoid arthritis * dementia * terminal neoplastic disease * no informed consent

Keywords: fracture of femoral neck
a study to assess the safety and clinical activity of azer-cel in participants with b-cell mediated autoimmune disorders

Conditions: B-cell Mediated Autoimmune Disorders

Summary: the main objective of the study is to determine the recommended phase 2 dose (rp2d) of azercabtagene zapreleucel (azer-cel).


Eligibility criteria:
inclusion criteria: 1. participants with progressive forms of multiple sclerosis including primary progressive and secondary progressive ms. 2. participants must have discontinued disease modifying therapy (dmt) prior to signing the icf and meet the following washout criteria prior to receiving lymphodepletion. exclusion criteria: 1. history of malignancy that has not been in remission for at least 2 years. 2. viral screening 1. evidence of chronic active or history of hepatitis b virus (hbv). 2. seropositive for human immunodeficiency virus (hiv) antibody. 3. history of bone marrow/hematopoietic stem cell or solid organ transplantation. 4. prior treatment with adoptive t-cell therapy or any gene therapy product directed at any target (e.g. car t-cell therapy). note: please note, other protocol specified inclusion/exclusion criteria may apply.

Keywords: progressive forms of multiple sclerosis (pms) primary progressive ms (ppms) secondary progressive ms (spms)
clinical trial of thoracoscopic lobecotmy under spontaneous ventilating anesthesia

Conditions: Non Small Cell Lung Cancer

Summary: with the development of video-assisted thoracoscopic surgery (vats) techniques and technology for anesthesia control, non-intubated anesthesia with spontaneous ventilation has been widely applied in vats. a prospective, multicentre, randomized controlled clinical study was applied in this study to assess the feasibility and safety of thoracoscopic lobectomy under spontaneous ventilation versus intubated single lung mechanical ventilation.

intubated anesthesia with single lung mechanical ventilation (slv) is considered the standard of care in vats. however, this type of anesthesia has been associated with several adverse effects, which can trigger complications and increase the overall surgical risk. in order to avoid intubated-anesthesia related adverse effects, spontaneous ventilation strategies have been proposed in recent years.encouraged by the satisfactory results with a preliminary experience of spontaneous ventilated vats, the multicentre randomized controlled clinical controled study is established to comparatively analyze the outcome of patients undergoing either nonintubated intravenous anesthesia with spontaneous ventilation (sv) or slv vats lobectomy, especially in safety during operation, lymph nodes resection, complication rate, muscle recovery after surgery, the difference the postoperative hospitalization time.

Eligibility criteria:
inclusion criteria: * volunteering to participate in clinical trials and having the ability of responsibility can be signed informed consent. * 18-70 years old • preoperative chest ct diagnosed with "localized lung bulla" and needing surgical treatment * eastern cooperative oncology group(ecog) score standard ≤ 1 • asa（american society of anesthesiologists score） ≤ 2 * heart ejection fraction( ef)≥ 50 exclusion criteria: * refusing to participate in clinical trials • a history of tuberculosis or other diseases could cause pleural adhesion or more pleural effusion * bmi ≥ 25 kg/m\^2 * other not suitable situation

Keywords: complications, postoperative/perioperative video assisted thoracic surgery non-intubated anaesthesia
patient centered mobile health technology enabled atrial fibrillation management

Conditions: Atrial Fibrillation; Behavior

Summary: the overall objective of this proposal is to evaluate the feasibility of a comprehensive digital atrial fibrillation (afib) management tool that will empower patients to a) take an active role in learning about afib management options, starting and adhering to evidence-based therapies and lifestyle changes and b) to guide the patients during afib episodes which are associated with anxiety and impairment in quality of life. researchers plan to evaluate the feasibility and preliminary efficacy of this novel digital toolkit in improving quality of life and decreasing afib burden in a pilot randomized clinical trial (rct).


Eligibility criteria:
inclusion criteria * 18 years or older * non- valvular paroxysmal atrial fibrillation exclusion criteria * non-english speaking * has previously been evaluated by a cardiologist or electrophysiologist * mitral stenosis * presence of artificial heart valve * severe valvular disease (any) * physical disability that would preclude technology use, safe and adequate exercise performance * hearing or visual impairment that would preclude technology use * history of fall one or more times in the last year * hypertrophic obstructive cardiomyopathy with peak resting left ventricular outflow gradient of \>25 mmhg * known aortic dissection * severe resting arterial hypertension (sbp \>200 mmhg or diastolic bp \>110mmhg) upon enrollment (obtained during clinic visit) * mental impairment leading to inability to cooperate with study procedures * untreated high degree atrioventricular block * atrial fibrillation with rapid ventricular rate (resting heart rate at enrollment visit \>110) upon enrollment (obtained during clinic visit) * history of cardiac arrest, sudden death * mi or cardiac surgery complications of cardiogenic shock and/or congestive heart failure (chf) and/or signs/symptoms of post-procedure ischemia * left ventricular ejection fraction \<40% * clinically significant depression * presence of implanted cardiac device * incomplete revascularization procedure * pregnancy * previous open-heart surgery * unsafe to participate in the program as per treating clinician

Keywords: remote patient monitoring atrial fibrillation risk factor modification digital health mobile health
a study to compare effectiveness of montelukast sodium with comparator in mild to moderate persistent asthmatics (0476-329)

Conditions: Asthma; Allergic Rhinitis

Summary: subjects have 8-week with montelukast sodium or comparator drug administration period, 2-week wash-out period and 8-week comparator drug or the drug administration period (with cross-over design) for assessment of the drug efficacy, safety and tolerability.


Eligibility criteria:
inclusion criteria: * males or females between the ages of 18 and 60 with mild to moderate asthma
durability at 20 years of quadrangular resection with annular plication for mitral regurgitation

Conditions: Mitral Valve Disease

Summary: degenerative mitral regurgitation (mr) due to prolapse of the posterior leaflet is the most common dysfunction of the mitral valve (mv) in the western world and is nowadays treated with a variety of surgical techniques. quadrangular resection combined with annular plication and annuloplasty, as originally described by carpentier, has been the standard approach for many years, before sliding/folding plasty and artificial chordae gained larger popularity.however, very few studies have been published on thevery long-term results (up to 20 years) of quadrangular resection and annular plication, often reporting only freedom from reoperation rather than from recurrent mr. this study aims to evaluate the very long-term (20 years) clinical and echocardiographic results of this approach, which was used for many years at the beginning of our mitral repair program.


Eligibility criteria:
inclusion criteria: * adult patients * affected by mitral valve posterior leaflet prolapse/flail causing severe mitral regurgitation * treated with quadrangular resection of the posterior leaflet and annulus plication exclusion criteria: * other patients